Aktionsplan Aadi Bioscience, Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
| Цена ао |
2.2 |
| Выручка |
0.000749 |
| EBITDA |
-0.0225 |
| Число акций ао |
0.02692 млрд |
| P/S |
34.68 |
| P/BV |
0.711 |
| EV/EBITDA |
0.55 |
| ISIN |
US00032Q1040 |
| Сайт |
https://aadibio.com
|
| Валюта |
usd |
| IPO date |
2017-08-08 |
| Sector |
Health Care |
| Industry |
Biotechnology |
| Валюта отчета |
usd |
| Preisänderung pro Tag: |
0% (2.13) |
| Preisänderung pro Woche: |
+7.04% (1.99) |
| Preisänderung pro Monat: |
+18.33% (1.8) |
| Preisänderung über 3 Monate: |
+39.22% (1.53) |
| Preisänderung über sechs Monate: |
+15.76% (1.84) |
| Preisänderung pro Jahr: |
-46.62% (3.99) |
| Preisänderung über 3 Jahre: |
-92.29% (27.63) |
| Preisänderung über 5 Jahre: |
+204.29% (0.7) |
| Preisänderung seit Jahresbeginn: |
-55.16% (4.75) |
|
|
Unterschätzung
| Name |
Bedeutung |
Grad |
| P/S |
2.18 |
7 |
| P/BV |
0.5041 |
10 |
| P/E |
0 |
0 |
| EV/EBITDA |
0.0395 |
10 |
| Gesamt: |
|
5.88 |
|
Effizienz
| Name |
Bedeutung |
Grad |
| ROA, % |
-49.66 |
0 |
| ROE, % |
-62.52 |
0 |
| Gesamt: |
|
0 |
|
|
|
Dividenden
| Name |
Bedeutung |
Grad |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| Gesamt: |
|
0 |
|
Pflicht
| Name |
Bedeutung |
Grad |
| Debt/EBITDA |
-0.0979 |
10 |
| Gesamt: |
|
9.8 |
|
Wachstumsimpuls
| Name |
Bedeutung |
Grad |
| Rentabilität Revenue, % |
3151.54 |
10 |
| Rentabilität Ebitda, % |
209.33 |
10 |
| Rentabilität EPS, % |
118.14 |
10 |
| Gesamt: |
|
10 |
|
| ETF |
Aktie, % |
Rentabilität für das Jahr, % |
Dividenden, % |
| iShares Micro-Cap ETF |
0.00821 |
34.327031588619 |
1.54048 |
|
|
|
|
| Aufsicht |
Berufsbezeichnung |
Zahlung |
Geburtsjahr |
| Dr. Neil P. Desai Ph.D. |
Founder & Executive Chairman |
710.35k |
1965 (59 Jahre) |
| Dr. Loretta M. Itri F.A.C.P., M.D. |
Chief Medical Officer |
617.45k |
1950 (74 Jahr) |
| Mr. David J. Lennon Ph.D. |
President, CEO & Director |
277.75k |
1971 (53 Jahr) |
| Mr. Scott M. Giacobello CPA |
CFO, Treasurer, Investor Relations & Corporate Communications |
643.23k |
1970 (54 Jahr) |
| Mr. Stephen M. Rodin J.D. |
Senior VP of Legal & General Counsel |
N/A |
1976 (48 Jahre) |
| Mr. Raymond G. Steitz |
Senior VP of Human Resources & Chief Human Resources Officer |
N/A |
1959 (65 Jahre) |
| Mr. Bryan Ball |
Chief Technical Operations Officer |
N/A |
1970 (54 Jahr) |
